Endothelial nitric oxide synthase gene: Prospects for treatment of heart disease

Pharmacogenomics

Volumn 8, Issue 12, 2007, Pages 1723-1734

  Cooke, Glen E ^a   Doshi, Amit ^a   Binkley, Philip F ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Atherosclerosis; Coronary heart disease; Endothelial dysfunction; Endothelial nitric oxide synthase; HMG CoA reductase inhibitors (statins); Ischemic heart diseases; Myocardial infarction; Nitric oxide; SNP

Indexed keywords

ARGININE; ASPARTIC ACID; ATORVASTATIN; CALCIUM ION; CALMODULIN; CD40 LIGAND; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLAVINE ADENINE NUCLEOTIDE; FLAVINE MONONUCLEOTIDE; FLUINDOSTATIN; GELATINASE B; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRATE; NITRIC OXIDE; NITRITE; PADGEM PROTEIN; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REPLICATION FACTOR A; SIMVASTATIN; TETRAHYDROBIOPTERIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASCULAR CELL ADHESION MOLECULE 1;

AMINO ACID SUBSTITUTION; BLOOD VESSEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DEATH; DINUCLEOTIDE REPEAT; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENZYME METABOLISM; ETHNIC DIFFERENCE; EXON; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; HAPLOTYPE; HEART DISEASE; HEART INFARCTION; HEART TRANSPLANTATION; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; JAPANESE; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PHARMACOGENETICS; POPULATION GENETICS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; EXONS; HAPLOTYPES; HEART DISEASES; HUMANS; INTRONS; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS);

EID: 37649012444     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.12.1723     Document Type: Review

References (99)

1. Thomas DD, Liu X, Kantrow SP, Lancaster JR: The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc. Natl Acad. Sci. USA 98(1), 355-360 (2001).
2. Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H: Guanylate cyclase activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin andmyoglobin. Adv. Cyclic Nucleotide Res. 9, 145-158 (1978).
3. Craven PA, DeRubertis FR: Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. J. Biol. Chem. 253(23), 8433-8443 (1978).
4. Stamler JS, Simon DI, Osborne JA et al.: S-Nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl Acad. Sci. USA 89, 444-448 (1992).
5. Arnold WP, Mittal CK, Katsuki S, Murad F: Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc. Natl Acad. Sci. USA 74(8), 3203-3207 (1977).
6. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (1980).
7. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl Acad. Sci. USA 84(24), 9265-929 (1987).
8. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526 (1987).
9. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ: Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced humnan platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57, 946-955 (1981).
10. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol. 6, 150-166 (2005).
11. Iwakiri Y, Satoh A, Chatterjee S et al.: Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc. Natl Acad. Sci. USA 103(52), 19777-19782 (2006).
12. Ziche ML, Morbidelli E, Masini et al.: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Investig. 94, 2036-2044 (1994).
13. Kawasaki K, Smith RS, Hsieh CM, Sun J, Chao J, Liao JK: Activation of the phospatidylinositol 3-kinase/protein kinase akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell. Biol. 23(16), 5726-5737 (2003).
14. Gooch KJ, Dangler CA, Frangos JA: Exogenous, basal, and flow-induced nitric oxide production and endothelial cell proliferation. J. Cell Physiol. 171, 252-258 (1997).
15. Dimmeler S, Haendeler J. Nehis M. Zeiher AM: Suppresion of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp Med. 185, 601-607 (1997).
16. Kim YM, Talanian RV, Billiar TR: Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J. Biol. Chem. 272, 31138-31148 (1997).
17. Dimmeler S, Zeiher AM: Nitric oxide-an endothelial cell survival factor. Cell Death Differ. 6, 964-968 (1999).
18. Mannick JB, Hausladen A, Liu L et al.: fas-induced caspase denitrosylation. Science 284, 651-654 (1999).
19. Bredt DS: Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic. Res. 31, 577-596 (1999).
20. Yetik-Anacak G, Catravas JD: Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul. Pharmacol. 45, 268-276 (2006).
21. Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333, 664-666 (1988).
22. Bredt DS, Snyder SH: Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc. Natl Acad. Sci. USA 87, 682-685 (1990).
23. Bredt DS, Hwang PM, Snyder SH: Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347(6295), 768-770 (1990).
24. Schmidt HH, Pollock JS, Nakane M, Gorsky LD, Förstermann U, Murad F: Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc. Natl Acad. Sci. USA 88(2), 365-369 (1991).
25. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF: Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: An FAD- and FMN-containing flavoprotein. Proc. Natl Acad. Sci. USA 88(17), 7773-7777 (1991).
26. Yui Y, Hattori R, Kosuga K et al.: Calmodulin-independent nitric oxide synthase from rat polymorphonuclear neutrophils. J. Biol. Chem. 266(6), 3369-3371 (1991).
27. Pollock JS, Förstermann U, Mitchell JA et al.: Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl Acad. Sci. USA 88, 10480-10484 (1991).
28. Stuehr DJ: Structure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 37, 339-359 (1997).
29. Shaul PW: Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol. 64, 749-774 (2002).
30. Sessa WC: eNOS at a glance. J. Cell Sci. 117, 2427-2429 (2004).
31. Förstermann U: Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol. Chem. 387, 1521-1533 (2006).
32. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH: Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351(6329), 714-718 (1991).
33. Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH: Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc. Natl Acad. Sci. USA 89, 6711-6715 (1992).
34. Lamas S, Marsden PA, Li GK, Tempst P, Michel T: Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc. Natl Acad. Sci. USA 89(14), 6348-6352 (1992).
35. Sessa WC, Harrison JK, Barber CM et al.: Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J. Biol. Chem. 267(22), 15274-1526 (1992).
36. Janssens SP, Shinnouchi A, Quertermous T, Bloch DB, Blouch KD: Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J. Biol. Chem. 267(21), 14519-14522 (1992).
37. Marsden PA, Heng HHQ, Scherer SW et al.: Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem. 268(23), 17478-17488 (1993).
38. Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F: Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem. Biophys. Res. Common. 198(3), 1027-1033 (1994).
39. Miyahara K, Kawamoto T, Sase K et al.: Cloning and structural characterization of the human endothetial nitric-oxide-synthase gene. Eur. J. Biochem. 223(3), 719-726 (1994).
40. Marsden PA, Schappert KT, Chen HS et al.: Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 307(3), 287-293 (1992).
41. Yoshimura M, Yasue H, Nakayama M et al.: A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum. Genet. 103(1), 65-69 (1998).
42. French JK, Van de Water NS, Sutton TM et al.: Potential thrombophilic mutations/polymorphisms in patients-with no flow-limiting stenosis after myocardial infarction. Am. Heart J. 145, 118-124 (2003).
43. Shimasaki Y, Yasue H, Yoshimura M et al.: Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J. Am. Coll. Cardiol. 31(7), 1506-1510 (1998).
44. Hibi K, Ishigami T, Tamura K et al.: Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 32, 521-526 (1998).
45. Hingorani AD, Liang CF, Fatibene J et al.: A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100, 1515-1520 (1999).
46. Colombo MG, Andreassi MG, Paradossi U et al.: Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298→Asp polymorphism) to the presence, extent, and severity of coronary artery disease. Heart 87, 525-528 (2002).
47. Rossi GP, Cesari M, Zanchetta M et al.: The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J. Am. Coll. Cardiol. 41, 930-937 (2003).
48. Rossi GP, Taddei S, Virdis A et al.: The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J. Am. Coll. Cardiol. 41, 938-945 (2003).
49. Cai H, Wilcken DEL, Wang XL: The Glu-298→Asp (894G→T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J. Mol. Med. 77, 511-514 (1999).
50. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD: Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a huge review. Am. J. Epidemiol. 164, 921-935 (2006).
51. Casas JP, Bautista LE, Humphries SE, Hingorani AD: Endothelial nitric oxide synthase genotype and ischemic heart disease. meta-analysis of 26 studies involving 23,028 subjects. Circulation 109, 1359-1365 (2004).
52. Spence MS, McGlinchey PG, Patterson CC et al.: Endothelial nitric oxide synthase gene polymorphism and ischemic heart disease. Am. Heart J. 148, 847-851 (2004).
53. Jeerooburkhan N, Jones LC, Bujac S et al.: Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 38, 1054-1061 (2001).
54. Rossi GP, Maiolino G, Zanchetta M et al.: The T-786C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients patients. J. Am. Coll. Cardiol. 48(6), 1166-1174 (2006).
55. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J: Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298. Proc. Natl Acad. Sci. USA 97(6), 2832-2835 (2000).
56. Fairchild TA, Fulton D, Fontana JT Gratton JP, McCabe TJ, Sessa WC: Acid hydrolysis as a mechanism for the cleavage of the Glu(298)→Asp variant of human endothelial nitric-oxide synthase. J Biol. Chem. 276, 26674-26679 (2001).
57. Joshi MS, Mineo C, Shaul PW, Bauer JA: Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J. 21, 2655-2663 (2007).
58. Persu A, Stoenoiu S, Messiaen T et al.: Modifier effect of eNOS in autosomal dominant polycystic kidney disease. Hum. Mol. Genet. 11 (3), 229-241 (2002).
59. Sofowora G, Dishy V, Xie HG et al.: In vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogentics 11 (9), 809-814 (2001).
60. Chrysohoou C, Panagiotakos DB, Pitsavos C et al.: Evidence for association between endothelial nitric oxide synthase gene polymorphism (G894T) and inflammatory markers: the ATTICA study. Am. Heart J. 148(4), 733-738 (2004).
61. Paradossi U, Ciofini E, Clerico A et al.: Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298←Asp and T-786←C polymorphisms. Stroke 35, 1305-1309 (2004).
62. Savvidou MD, Vallance PJT, Nicolaides KH, Hingorani AD: Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 38, 1289-1293 (2001).
63. Leeson CPM, Hingorani AD, Mullen MJ et al.: Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ. Res. 90, 1153-1158 (2002).
64. Nakayama M, Yasue H, Yoshimura M et al.: T-786C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99, 2864-2870 (1999).
65. Wang J, Dudley D, Wang XL: Haplotype-specific effects on endothelial no synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler. Thromb. Vasc. Biol. 22(5), E1-E4 (2002).
66. Miyamoto Y, Saito Y, Nakayama M et al.: Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T→C mutation associated with coronary spastic angina. Hum. Mol. Genet. 9(18), 2629-2637 (2000).
67. Nagassaki S, Metzger IF, Souza-Costa DC, Marroni AS, Uzuelli JA, Tanus-Santos JE: eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb. Res. 115, 375-379 (2005).
68. Abe K, Nakayama M, Yoshimura M et al.: Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T>C polymorphism. Pharmacogenet. Genomics. 15(5), 329-336 (2005).
69. Nagassaki S, Sertório JT, Metzger IF, Bem AF, Rocha JB, Tanus-Santos JE: eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic. Biol. Med. 41, 1044-1049 (2006).
70. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE: Anti-inflammatory effects of atorvastatin: modulation by T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193, 438-444 (2007).
71. Binkley PF, Nunziatta E, Liu-Stratton Y, Cooke GE: A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. Am. Heart J. 149, 342-348 (2005).
72. Wang XL, Sim AS, Badenhop RF. McCredie RM, Wilcken DEL: A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat. Med. 2(1), 41-45 (1996).
73. Tsukada T, Yokoyama K, Arai T et al.: Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem. Biophys. Res. Commun. 245(1), 190-193 (1998).
74. Zhang MX, Ou H, Shen YH et al.: Regulation of endothelial nitric oxide synthase by small RNA. Proc. Natl Acad. Sci. USA 102(47), 16967-16972 (2005).
75. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
76. Shepherd J, Cobbe SM, Ford I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
77. Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Trial Investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
78. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.. 339, 1349-1357 (1998).
79. Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
80. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7-22 (2002).
81. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135 (1998).
82. Kano H, Hayashi T, Sumi D et al.: A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA. Biochem. Biophys. Res. Commun. 259, 414-419 (1999).
83. Sumi D, Hayashi T, Thakur NK et al.: A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 155, 347-357 (2001).
84. Treasure CB, Klein JL, Weintraub WS et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332(8), 481-487 (1995).
85. Wassermann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G: Rapid effect of 3-Hydroxy-3methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 93, E98-E103 (2003).
86. Tiefenbacher CP, Friedrich S, Bleeke T, Vahl C, Chen X, Niroomand F: ACE inhibitors and statins acutely improve endothelial dysfunction of human arterioles. Am. J. Physiol. Heart Circ. Physiol. 286, H1425-H1432 (2004).
87. Böger GI, Rudolph TK, Maas R et al.: Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin. effect of combination with oral L-arginine. J. Am. Coll. Cardiol. 49(23), 2274-2282 (2007).
88. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342(3), 145-153 (2000).
89. The European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind placebo-controlled, multi-centre trial (EUROPA). Lancet 362, 782-788 (2003).
90. Ceconi C, Fox KM, Remme WJ et al.: ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovascular Research 73, 237-46 (2007).
91. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS: Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90, 974-082 (2002).
92. Mancini GBJ, Henry GC, Macaya C et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENDothelial Dysfunction) Study. Circulation 94, 258-265 (1996).
93. McNamara DM, Holubkov R, Postava L et al.: Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 107, 1598-1602 (2003).
94. Metzger IF, Souza-Costa DC, Marroni AS, et al.: Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet. Genomics. 15(8), 0565-570 (2005).
95. Metzger IF, Sertório JT, Tanus-Santos JE: Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic. Biol. Med. 43, 987-992 (2007).
96. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos JE: Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186, 428-432 (2006).
97. Searles CD: Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. Am. J. Physiol. Cell Physiol. 291, C803-C816 (2006).
98. Feron O, Balligand JL: Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovascular Research 69, 788-797 (2006).
99. Mount PF, Kemp BE, Power DA: Regulation of endothelial and myocardial NO synthase by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol. 42, 271-9 (2007).